Skip to main
ASMB

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences is well-positioned with multiple potential treatments in its pipeline, strong partnerships in place, and a solid financial position. While there are risks involved, the potential for success for these treatments and the potential for milestone payments and partnerships make this stock an attractive opportunity for investors, with a target price of $50 per share.

Bears say

Assembly Biosciences is facing a critical decision in mid-2026 regarding their partnership with Gilead for the development of their long-acting helicase-primase inhibitors (HPI) for recurrent genital herpes, which could potentially replace their traditional milestones and royalties. However, with a relatively small U.S. market for hepatitis delta virus and a risk-adjusted value of $21 per share for their HPI franchise in recurrent genital herpes, a negative outlook is warranted due to the uncertainty and limited market potential for their pipeline products.

Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.

According to 4 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.